OraSure Technologies Appoints Eamonn P. Hobbs to its Board of Directors
March 23 2016 - 6:00AM
OraSure Technologies, Inc. (NASDAQ:OSUR), today announced the
appointment of Mr. Eamonn P. Hobbs as a member of the Company's
Board of Directors. Mr. Hobbs will serve as a Class I
Director with an initial term expiring at the Company’s 2016 Annual
Meeting of Stockholders. He will also serve on the Company’s
Audit and Compensation Committees.
"We are delighted to welcome Eamonn Hobbs as a new member of our
Board of Directors," said Douglas G. Watson, Chairman of the Board
of OraSure Technologies. "Eamonn's executive leadership,
board experience and extensive background in the medical device
industry, make him an excellent addition to our Board."
Mr. Hobbs has over 30 years of experience in the medical device
industry including the specialty fields of interventional
radiology, vascular surgery, interventional cardiology, surgical
oncology, and gastroenterology. He most recently served as
President and Chief Executive Officer at Antares Pharma, Inc.,
(NASDAQ:ATRS) a small cap pharmaceutical company based in Ewing,
N.J. Previously, he served as President and Chief Executive
Officer at Delcath Systems Inc., a specialty pharmaceutical and
medical device company focused on oncology. Hobbs also served on
the Board of Directors of both Antares Pharma and Delcath
Systems.
Prior to Delcath, Mr. Hobbs co-founded AngioDynamics, Inc. in
1988 and served as the Company’s President and Chief Executive
Officer until 2008. During his tenure there, he built the
Company into a global market leader with more than $200 million in
revenues and 700 employees.
Mr. Hobbs served as Chairman of the Board of Directors of the
Medical Device Manufacturers Association from 2010 to 2013. He
currently is Chairman of the Board of Marvao Medical, Inc., a
medical technology company based in Galway, Ireland and serves on
the Board of Directors of Harmonic Medical, Inc., a development
stage medical device company based in Toronto, Canada.
In 2006, Mr. Hobbs was granted an honorary fellowship in the
Society of Interventional Radiology, which was only the third
honorary fellowship ever granted a non-physician in the Society’s
40-year history. He received his Bachelor of Science in Plastics
Engineering from the University of Massachusetts, and in 2010, he
was honored by the University with the “Francis Cabot Lowell Award
for Outstanding Achievement in Business.”
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of point of care diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its first-to-market, innovative products
include rapid tests for the detection of antibodies to HIV and HCV
on the OraQuick® platform, oral fluid sample collection,
stabilization and preparation products for molecular diagnostic
applications, and oral fluid laboratory tests for detecting various
drugs of abuse. OraSure's portfolio of products is sold globally to
various clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, research and
academic institutions, distributors, government agencies,
physicians' offices, commercial and industrial entities and
consumers. The Company's products enable healthcare providers to
deliver critical information to patients, empowering them to make
decisions to improve and protect their health.
For more information on OraSure Technologies, please visit
www.orasure.com.
Investor Contact:
Ronald H. Spair
Chief Financial Officer
(610) 882-1820
investorinfo@orasure.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024